Aquestive Therapeutics, Inc. (NASDAQ:AQST)’s stock price traded down 6.5% on Friday . The stock traded as low as $6.72 and last traded at $6.74. 820,205 shares traded hands during mid-day trading, a decline of 9% from the average session volume of 900,558 shares. The stock had previously closed at $7.21.

A number of analysts have recently commented on AQST shares. Royal Bank of Canada cut their price target on Aquestive Therapeutics from $8.00 to $7.00 and set an “outperform” rating on the stock in a research note on Monday, September 28th. HC Wainwright lowered their target price on Aquestive Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, September 28th. BMO Capital Markets decreased their price objective on Aquestive Therapeutics from $18.00 to $13.00 in a report on Monday, September 28th. Wedbush reaffirmed a “buy” rating and set a $33.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, September 2nd. Finally, JMP Securities cut their target price on Aquestive Therapeutics from $23.00 to $17.00 and set an “outperform” rating on the stock in a research report on Monday, September 28th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $14.29.

The company has a fifty day moving average price of $5.32 and a 200-day moving average price of $5.87. The stock has a market capitalization of $226.60 million, a P/E ratio of -4.41 and a beta of 3.81.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, November 9th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.03). Analysts expect that Aquestive Therapeutics, Inc. will post -1.54 earnings per share for the current year.

Large investors have recently made changes to their positions in the business. Telemus Capital LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $50,000. Virtu Financial LLC purchased a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth about $53,000. Jane Street Group LLC purchased a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth about $54,000. American International Group Inc. purchased a new position in Aquestive Therapeutics in the 2nd quarter valued at about $59,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Aquestive Therapeutics in the 2nd quarter valued at about $62,000. Institutional investors and hedge funds own 53.80% of the company’s stock.

About Aquestive Therapeutics (NASDAQ:AQST)

Aquestive Therapeutics, Inc, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

See Also: How does a reverse stock split work?

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.